Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Progress In The Management Of Malignant Pleural Mesothelioma In 2017

Amanda J McCambridge, A. Napolitano, A. Mansfield, D. Fennell, Y. Sekido, A. Nowak, T. Reungwetwattana, W. Mao, H. Pass, M. Carbone, H. Yang, T. Peikert
Published 2018 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
ABSTRACT Malignant pleural mesothelioma (MPM) is an uncommon, almost universally fatal, asbestos‐induced malignancy. New and effective strategies for diagnosis, prognostication, and treatment are urgently needed. Herein we review the advances in MPM achieved in 2017. Whereas recent epidemiological data demonstrated that the incidence of MPM‐related death continued to increase in United States between 2009 and 2015, new insight into the molecular pathogenesis and the immunological tumor microenvironment of MPM, for example, regarding the role of BRCA1 associated protein 1 and the expression programmed death receptor ligand 1, are highlighting new potential therapeutic strategies. Furthermore, there continues to be an ever‐expanding number of clinical studies investigating systemic therapies for MPM. These trials are primarily focused on immunotherapy using immune checkpoint inhibitors alone or in combination with other immunotherapies and nonimmunotherapies. In addition, other promising targeted therapies, including pegylated adenosine deiminase (ADI‐PEG20), which focuses on argininosuccinate synthase 1–deficient tumors, and tazemetostat, an enhancer of zeste 2 polycomb repressive complex 2 subunit inhibitor of BRCA1 associated protein 1 gene (BAP1)‐deficient tumors, are currently being explored.
This paper references
10.1097/JTO.0000000000000214
Measles Vaccine Strains for Virotherapy of Non–Small-Cell Lung Carcinoma
M. Patel (2014)
10.1097/00000658-199507000-00013
Treatment of Experimental Human Mesothelioma Using Adenovirus Transfer of the Herpes Simplex Thymidine Kinase Gene
W. Smythe (1995)
10.1016/j.jtcvs.2015.09.121
Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy.
H. Batırel (2016)
10.1097/PAS.0000000000000852
Identification of DAB2 and Intelectin-1 as Novel Positive Immunohistochemical Markers of Epithelioid Mesothelioma by Transcriptome Microarray Analysis for Its Differentiation From Pulmonary Adenocarcinoma
Masatsugu Kuraoka (2017)
10.1016/j.radonc.2017.08.003
The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review.
M. Ashton (2017)
10.1093/ejcts/ezx079
Pleurectomy–decortication in malignant pleural mesothelioma: are different surgical techniques associated with different outcomes? Results from a multicentre study†
G. Marulli (2017)
10.1016/j.jtcvs.2014.03.011
Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality.
B. Burt (2014)
10.1158/1078-0432.CCR-17-1345
Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses
L. Schunselaar (2017)
10.1038/onc.2015.243
Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma
A. Napolitano (2016)
10.1200/JCO.2017.35.18_SUPPL.LBA8507
Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial
A. Scherpereel (2017)
10.1016/S1470-2045(16)30498-3
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
C. Langer (2016)
10.1158/1078-0432.CCR-16-0844
Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma
Licun Wu (2016)
10.1016/j.humpath.2017.04.032
Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
S. Inaguma (2018)
10.1158/1078-0432.CCR-17-2169
A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma
M. Zauderer (2017)
[Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus].
Z. Xia (2004)
10.1001/jamaoncol.2016.5487
Association of Asbestos Exposure With Malignant Mesothelioma Incidence in Eastern China
W. Mao (2017)
Computeraided volumetric assessment of malignant pleural mesothelioma on CTusing a randomwalk-basedmethod
M Chen (2017)
10.1056/NEJMOA1606774
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
M. Reck (2016)
10.1093/ejcts/ezv398
Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma.
Arthur Kostron (2016)
10.1245/s10434-006-9127-4
Radiation-Induced Cellular DNA Damage Repair Response Enhances Viral Gene Therapy Efficacy in the Treatment of Malignant Pleural Mesothelioma
P. Adusumilli (2006)
10.1016/j.ajpath.2013.07.029
Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-α signaling.
Fang Wei Qi (2013)
10.18632/oncotarget.20845
Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1
Takashi Eguchi (2017)
10.1200/JCO.2017.35.15_SUPPL.8558
Tremelimumab in combination with durvalumab in first or second-line mesothelioma patients: Safety analysis from the phase II NIBIT-MESO-1 study.
L. Calabrò (2017)
10.1016/j.canlet.2017.06.028
Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.
M. Betti (2017)
10.1016/j.jtho.2017.02.013
The Immune Microenvironment, Genome‐wide Copy Number Aberrations, and Survival in Mesothelioma
B. Thapa (2017)
10.1186/1479-5876-10-179
BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
M. Carbone (2012)
10.1371/journal.pone.0121071
Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
S. Cedrés (2015)
10.1200/JCO.2004.11.120
Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies.
F. Izzo (2004)
10.1183/13993003.02534-2016
The asbestos fibre burden in human lungs: new insights into the chrysotile debate
I. Feder (2017)
10.1038/onc.2017.266
Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma
Agata Szymiczek (2017)
10.18632/oncotarget.17436
Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis
Long Tian (2017)
10.1016/j.jtho.2016.12.019
BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas
N. Leblay (2017)
10.1001/jama.2017.17426
Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial
Rajesh Thomas (2017)
10.1200/JCO.2016.67.2675
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.
A. Rimner (2016)
10.1038/bjc.2017.269
Evaluating the effect of immune cells on the outcome of patients with mesothelioma
S. Chee (2017)
10.1160/ME9050
Computer-assisted diagnosis for early stage pleural mesothelioma: towards automated detection and quantitative assessment of pleural thickening from thoracic CT images.
K. Chaisaowong (2007)
10.1016/S1470-2045(15)00208-9
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
R. Stahel (2015)
10.1073/pnas.1612074113
High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma
Yoshie Yoshikawa (2016)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/j.jtho.2016.04.028
Consensus Report of the 2015 Weinman International Conference on Mesothelioma
M. Carbone (2016)
10.1038/bjc.2017.62
First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers
E. Angevin (2017)
Incidence and distribution of argininosuccinate synthetase de fi ciency in human
BJ Dillon
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation
BJ Dillon (2004)
10.1158/1078-0432.CCR-15-1130
HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
A. Napolitano (2016)
10.1097/PAS.0000000000000935
PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma
D. Chapel (2017)
10.1016/j.ejrad.2009.02.002
Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma.
Guntulu Ak (2010)
10.1002/ijc.10996
Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF‐C autocrine loops
R. Masood (2003)
10.1200/JCO.2016.34.15_SUPPL.8503
Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.
R. Hassan (2016)
10.1038/modpathol.2016.181
MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma
V. Amatya (2017)
10.1038/sj.bjc.6605856
A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients
T-S Yang (2010)
10.1093/neuonc/not310
Glioma virus therapies between bench and bedside.
J. Kaufmann (2014)
10.1038/ng.3520
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
R. Bueno (2016)
Radiologicpathologic correlation of mesothelioma tumor
SG 3rdArmato (2015)
10.1158/1535-7163.MCT-07-0483
Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer
M. Li (2008)
10.1016/j.lungcan.2013.11.026
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
10.1016/j.jtcvs.2015.09.129
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
M. D. de Perrot (2016)
10.1016/J.JTHO.2016.11.301
OA13.02 Phase II Trial of Pembrolizumab in Patients with Malignant Mesothelioma (MM): Interim Analysis
H. Kindler (2017)
10.1093/ejcts/ezw074
Impact of induction therapy on postoperative outcome after extrapleural pneumonectomy for malignant pleural mesothelioma: does induction-accelerated hemithoracic radiation increase the surgical risk?
P. Mordant (2016)
10.21873/ANTICANRES.11663
Puzzling Results from BAP1 Germline Mutations Analysis in a Group of Asbestos-Exposed Patients in a High-risk Area of Northeast Italy.
C. Rizzardi (2017)
10.1093/annonc/mdt161
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.
J. Wolchok (2013)
10.1016/S1470-2045(13)70381-4
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity.
Yinfei Tan (2017)
10.1183/09031936.00146110
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
T. Frauenfelder (2011)
10.1158/1535-7163.MCT-16-0821
Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss–Driven Tumorigenesis
Jonathan Cooper (2017)
10.1002/jcp.22724
Malignant mesothelioma: Facts, Myths, and Hypotheses
M. Carbone (2012)
10.18632/oncotarget.15814
Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma
S. Inaguma (2017)
10.1002/cncy.21917
Determination of PD‐L1 expression in effusions from mesothelioma by immuno‐cytochemical staining
Mohammed S I Mansour (2017)
10.1016/S2213-2600(15)00092-2
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
L. Calabrò (2015)
10.1016/j.jtho.2016.12.006
Improving the Accuracy of Mesothelioma Diagnosis in China
Zhenying Guo (2017)
10.1097/PAS.0000000000000864
A Subset of Malignant Mesotheliomas in Young Adults Are Associated With Recurrent EWSR1/FUS-ATF1 Fusions
P. Desmeules (2017)
10.1136/oemed-2017-104383
Non-occupational exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis
G. Marsh (2017)
10.21873/CGP.20023
A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ.
J. Creaney (2017)
10.21037/atm.2017.03.41
The impact of surgical approach on quality of life for pleural malignant mesothelioma.
R. Schwartz (2017)
10.21037/tlcr.2017.05.06
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.
Z. Chen (2017)
10.1200/JCO.2017.72.9012
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
F. Grosso (2017)
10.1158/0008-5472.CAN-14-0337
Discovery of mesothelin and exploiting it as a target for immunotherapy.
I. Pastan (2014)
10.1016/J.JTHO.2016.11.1518
P2.06-025 DREAM - A Phase 2 Trial of DuRvalumab with First Line chEmotherApy in Mesothelioma with a Safety Run In: Topic: Mesothelioma and SCLC
A. Nowak (2017)
10.18632/oncotarget.20465
Common, germline genetic variations in the novel tumor suppressor BAP1 and risk of developing different types of cancer
M. Lin (2017)
10.1016/j.humpath.2016.09.026
BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
S. McGregor (2017)
10.1016/j.ygyno.2011.06.021
Oncolytic virotherapy of breast cancer.
A. Hartkopf (2011)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1016/j.jtho.2017.09.1968
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma
N. S. Patil (2018)
10.1155/2017/9280170
Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma
D. Weber (2017)
10.1016/S1470-2045(17)30621-6
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
N. van Zandwijk (2017)
10.1016/J.JSS.2012.10.834
An Oncolytic Vaccinia Virus Expressing the Human Sodium Iodine Symporter Prolongs Survival and Facilitates SPECT/CT Imaging in an Orthotopic Model of Malignant Pleural Mesothelioma
Laurence J. Belin (2013)
10.1016/j.ijrobp.2011.09.027
Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.
K. Rosenzweig (2012)
10.1186/s12885-017-3375-5
Calretinin as a blood-based biomarker for mesothelioma
G. Johnen (2017)
10.1038/srep32643
Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo
D. Greening (2016)
10.1016/J.ACRA.2005.05.021
Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans.
S. Armato (2005)
10.1093/carcin/bgu227
Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.
F. Baumann (2015)
10.1016/J.JTHO.2017.09.329
OA 02.02 Ipilimumab and Nivolumab in the Treatment of Recurrent Malignant Pleural Mesothelioma: A Phase II Study
M. Disselhorst (2017)
10.1007/s11548-016-1511-3
Computer-aided volumetric assessment of malignant pleural mesothelioma on CT using a random walk-based method
Mitchell Chen (2016)
10.1080/10937404.2016.1195323
Mesothelioma from asbestos exposures: Epidemiologic patterns and impact in the United States
R. Lemen (2016)
10.1038/nature22798
BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation
A. Bononi (2017)
10.18632/oncotarget.20317
Diagnostic accuracy of BRCA1–associated protein 1 in malignant mesothelioma: a meta-analysis
Liming Wang (2017)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.21037/tlcr.2017.06.02
Drug development against the hippo pathway in mesothelioma.
G. Woodard (2017)
10.1016/j.jtho.2017.10.016
Dysregulated Expression of the MicroRNA miR‐137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma
T. G. Johnson (2018)
10.1016/j.jtho.2017.05.024
Tumor Suppressor microRNAs Contribute to the Regulation of PD‐L1 Expression in Malignant Pleural Mesothelioma
S. Kao (2017)
10.1016/S0169-5002(18)30098-9
Prophylactic irradiation of tracts (PIT) in patients with pleural mesothelioma: results of a multicentre phase III trial
N. Bayman (2018)
10.1186/s12885-017-3209-5
Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin
Guntulu Ak (2017)
10.7314/APJCP.2012.13.10.4849
Malignant mesothelioma in Eastern Asia.
C. Bianchi (2012)
10.1038/nrc3239
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
10.1371/journal.pgen.1005633
Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s
M. Carbone (2015)
10.1016/j.cllc.2017.03.010
LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
Giorgio V. Scagliotti (2017)
10.1016/J.JTHO.2017.09.330
OA 02.03 Prophylactic Irradiation of Tracts (PIT) in Patients with Pleural Mesothelioma: Results of a Multicenter Phase III Trial
N. Bayman (2017)
10.1016/j.jtho.2017.02.026
Improved Outcomes with Modern Lung‐Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma
F. Shaikh (2017)
10.1016/J.JTHO.2017.09.634
MA 19.01 A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)
Y. Goto (2017)
10.1093/ANNONC/MDY374.003
A phase II study of nivolumab: a multicenter, open-label, single arm study in malignant pleural mesothelioma (MERIT).
K. Aoe (2018)
10.1038/s41598-017-02694-0
Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism
Chiara de Santi (2017)
10.1038/cddis.2015.153
Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression
H. Yang (2015)
10.1200/JCO.2017.35.15_SUPPL.TPS8582
ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma.
P. Szlosarek (2017)
10.1016/j.cell.2015.09.001
Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
A. Serrels (2015)
10.1001/jamaoncol.2016.3049
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial
P. Szlosarek (2017)
10.1002/cncr.20057
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers
B. Dillon (2004)
10.1038/sj.cgt.7700594
Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma
Laurence Cordier Kellerman (2003)
10.1097/JTO.0b013e3181dd0ef1
Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed Tomography Scans
F. Liu (2010)
10.1158/0008-5472.CAN-14-1328
Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.
Jinfei Xu (2014)
10.1016/S1470-2045(17)30459-X
Radiotherapy for the treatment of malignant pleural mesothelioma.
M. Perrot (2017)
10.1016/j.jtho.2016.09.123
The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation
H. Pass (2016)
10.1016/j.lungcan.2014.11.019
Radiologic-pathologic correlation of mesothelioma tumor volume.
S. Armato (2015)
10.1016/j.jtho.2016.09.124
The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma
V. Rusch (2016)
10.1016/j.athoracsur.2014.09.056
Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma.
E. Taioli (2015)
10.1097/JTO.0000000000000471
High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma
Masaki Nasu (2015)
10.1158/2159-8290.CD-15-0583
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.
A. Morello (2016)
10.1038/modpathol.2016.188
Genomic Profiling of Malignant Peritoneal Mesothelioma Reveals Recurrent Alterations in Epigenetic Regulatory Genes BAP1, SETD2, and DDX3X
N. Joseph (2017)
10.1002/jgm.877
Imaging and therapy of malignant pleural mesothelioma using replication‐competent herpes simplex viruses
P. Adusumilli (2006)
10.1038/nm.3947
Loss of BAP1 function leads to EZH2-dependent transformation
Lindsay M. LaFave (2015)
10.1038/nrc.2017.42
Novel insights into mesothelioma biology and implications for therapy
T. Yap (2017)
10.1165/AJRCMB.13.1.7598939
Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer.
H. Hwang (1995)
10.1158/1078-0432.CCR-06-1101
In vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion
P. Szlosarek (2006)
10.18632/oncotarget.19872
Modulating BAP1 expression affects ROS homeostasis, cell motility and mitochondrial function
Lucie Hébert (2017)
10.1016/j.jtho.2016.08.147
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
A. Nowak (2016)
10.1136/oemed-2017-104298
Estimation of the global burden of mesothelioma deaths from incomplete national mortality data
Chimed-Ochir Odgerel (2017)
10.1016/j.jtho.2017.11.003
National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma.
Zaid M Abdelsattar (2018)
10.1200/JCO.2016.68.3672
Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
R. Hassan (2016)
10.1038/cgt.2010.10
Oncolytic measles viruses encoding interferon β and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy
H. Li (2010)
10.1148/RADIOL.2401050727
Quantification of lung tumor volume and rotation at 3D dynamic parallel MR imaging with view sharing: preliminary results.
C. Plathow (2006)
10.1093/ANNONC/MDW574.031
58P PDL1 expression associated with worse survival outcome in malignant pleural mesothelioma
Bella Nguyen (2016)
10.1136/oemed-2016-104133
Dose-time-response association between occupational asbestos exposure and pleural mesothelioma
A. Lacourt (2017)
10.4161/cbt.5.1.2237
Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma
P. Adusumilli (2006)
10.1002/DC.20767
Immunohistochemical expression and distribution of VEGFR‐3 in malignant mesothelioma
A. L. Filho (2007)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1038/modpathol.2017.108
Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma
M. Vivero (2018)
10.1001/jamaoncol.2017.2918
Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma
Y. Hung (2018)
Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity.
M. Odaka (2001)
10.1080/09537104.2016.1246712
Pretreatment thrombocytosis as a significant prognostic factor in malignant mesothelioma: a meta-analysis
Y. Zhuo (2017)
10.1158/1078-0432.CCR-16-1667
Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient–Derived Xenografts and Mesothelin as a Biomarker of Tumor Response
J. Zhang (2016)
10.1158/2326-6066.CIR-16-0330
Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity
Yasmin Leshem (2017)
10.1016/S1470-2045(17)30169-9
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
E. Alley (2017)
10.1111/his.13123
Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma
A. Shinozaki-Ushiku (2017)
10.1097/PAS.0000000000000825
GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung
Kyra B. Berg (2017)
10.1016/j.jtho.2017.03.023
A Novel BRCA1‐Associated Protein‐1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1‐Mediated DNA Repair
R. Parrotta (2017)
10.2217/imt-2017-0121
Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.
M. Reck (2018)
10.1016/J.JTHO.2016.11.300
OA13.01 A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational Research (TR) Biopies
J. Quispel-Janssen (2017)
10.1002/path.824
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
L. Strizzi (2001)
10.1016/S1470-2045(13)70257-2
Asbestos is not just asbestos: an unrecognised health hazard.
F. Baumann (2013)
10.1016/j.ijrobp.2014.05.032
Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma.
A. Rimner (2014)
10.1016/j.lungcan.2016.12.017
Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
T. Hida (2017)
10.1073/pnas.1309085110
Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair
Helen Yu (2013)
10.1001/jamadermatol.2017.2330
Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature
A. Haugh (2017)
Subcutaneous tumor growth complicating the positioning of Denver shunt and intrapleural port-à-cath in mesothelioma patients.
B. van Ooijen (1992)
10.1200/JCO.2016.71.3230
Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers
E. Beddowes (2017)
10.1200/JCO.2014.58.3377
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
R. Andtbacka (2015)
10.1183/13993003.02204-2017
Correspondence regarding the article “The asbestos fibre burden in human lungs: new insights into the chrysotile debate”
I. Feder (2017)
10.1016/j.athoracsur.2016.06.069
A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.
V. Rusch (2016)
10.1038/nm.4123
Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy
H. Jiang (2016)
10.1158/1078-0432.CCR-17-1172
Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition
J. Quispel-Janssen (2017)
10.1200/JCO.2005.02.0933
Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.
P. Ascierto (2005)
10.1158/1078-0432.CCR-12-2641
ASS1 as a Novel Tumor Suppressor Gene in Myxofibrosarcomas: Aberrant Loss via Epigenetic DNA Methylation Confers Aggressive Phenotypes, Negative Prognostic Impact, and Therapeutic Relevance
H. Huang (2013)
10.1093/CARCIN/BGW084
Modeling mesothelioma utilizing human mesothelial cells reveals involvement of phospholipase-C beta 4 in YAP-active mesothelioma cell proliferation.
T. Kakiuchi (2016)
Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma: a phase II study
M Disselhorst (2017)
10.1016/j.lungcan.2017.05.012
Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial.
M. Zhan (2017)
10.1118/1.3525836
Computerized segmentation and measurement of malignant pleural mesothelioma.
W. Sensakovic (2011)
10.1097/JTO.0b013e31828354c8
Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma
Z. Labby (2013)
10.1111/ajco.12788
PD‐L1 expression associated with worse survival outcome in malignant pleural mesothelioma
B. Nguyen (2018)
10.1038/ng.912
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
10.1093/ANNONC/MDX367.001
366PDOncolytic herpesvirus therapy for mesothelioma: A phase I/IIa trial of intrapleural administration of HSV1716 (NCT01721018)
S. Danson (2017)
10.1038/srep45768
HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma
S. Tsuji (2017)
10.1002/dc.23683
Utility of BRCA1‐associated protein 1 immunoperoxidase stain to differentiate benign versus malignant mesothelial proliferations in cytologic specimens
Z. McCroskey (2017)
10.1158/1078-0432.CCR-16-1971
Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma
R. Tranchant (2016)
10.1016/J.JTHO.2017.09.328
OA 02.01 Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma
H. Kindler (2017)
10.21037/atm.2017.05.23
Volumetric assessment in malignant pleural mesothelioma.
D. Murphy (2017)
10.1038/nrc3459
BAP1 and cancer
M. Carbone (2013)
10.1016/S1470-2045(17)30446-1
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
M. Maio (2017)
10.1016/J.JTHO.2017.09.333
OA 02.07 Surgical Selection in Pleurectomy Decortication for Mesothelioma – an Overview from Screening and Selection from MARS 2 Pilot
M. Trialists (2017)
10.1016/J.JTHO.2016.11.305
OA13.07 Intrapleural Modified Vaccine Strain Measles Virus Therapy for Patients with Malignant Pleural Mesothelioma
T. Peikert (2017)
10.3389/fonc.2017.00179
Oncolytic Viral Therapy for Mesothelioma
D. Pease (2017)
10.1371/journal.pone.0176680
Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease
T. Cavalleri (2017)
10.1016/j.jtho.2016.04.033
Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis
S. Noonan (2016)
10.15585/mmwr.mm6608a3
Malignant Mesothelioma Mortality — United States, 1999–2015
J. Mazurek (2017)
10.1183/13993003.01428-2016
Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma
M. D. de Perrot (2017)
10.1016/J.JTHO.2017.09.331
OA 02.05 RESPECT-MESO: An International Randomized Controlled Trial to Assess Early Specialist Palliative Care in Malignant Pleural Mesothelioma
F. Brims (2017)
10.1097/JTO.0000000000000064
Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma?: A Multicenter Retrospective Analysis of 1365 Consecutive Patients
P. Bovolato (2014)
10.1200/JCO.2009.26.7765
Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.
Evan S Glazer (2010)
10.1080/2162402X.2017.1373235
The “don't eat me” signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma
C. Schürch (2017)
10.1002/1878-0261.12150
A link between the fibroblast growth factor axis and the miR‐16 family reveals potential new treatment combinations in mesothelioma
K. Schelch (2018)
10.1158/1078-0432.CCR-17-2522
Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human
J. Aerts (2017)
10.18632/oncotarget.6285
Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response
C. Achard (2015)
10.1038/cdd.2017.95
Germline BAP1 mutations induce a Warburg effect
A. Bononi (2017)
10.1038/nature15529
Diversion of aspartate in ASS1-deficient tumors fosters de novo pyrimidine synthesis
Shiran Rabinovich (2015)
10.18632/oncotarget.15404
Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis
N. Chen (2017)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1016/j.athoracsur.2016.08.071
Extended Pleurectomy-Decortication-Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years.
J. Friedberg (2017)
10.1016/j.ejso.2017.05.009
Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study.
S. Valmary-Degano (2017)
10.1002/AJIM.4700030305
Occupational exposure to asbestos: population at risk and projected mortality--1980-2030.
W. Nicholson (1982)
10.1038/s41598-017-16551-7
Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma
T. Klikovits (2017)
10.1097/JTO.0000000000000177
B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
A. Mansfield (2014)
10.1200/JCO.2017.73.8401
Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.
D. Nelson (2017)
10.1200/JCO.2017.35.15_SUPPL.TPS8581
Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.
G. Zalcman (2017)
10.18632/oncotarget.15152
HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma
L. Pellegrini (2017)
10.1093/annonc/mds535
Disease volumes as a marker for patient response in malignant pleural mesothelioma.
Z. Labby (2013)
10.1016/j.jtho.2016.09.121
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
D. Rice (2016)



This paper is referenced by
10.1016/j.jtcvs.2019.12.076
Paclitaxel-loaded expansile nanoparticles improve survival following cytoreductive surgery in pleural mesothelioma xenografts.
Ngoc-Quynh T. Chu (2020)
10.1007/978-3-030-16884-1_4
Genetics and Epigenetics of Mesothelioma
A. Aspesi (2019)
10.1097/MD.0000000000014979
Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma
Ruiyue Gao (2019)
10.2147/CMAR.S201269
High systemic immune–inflammation index represents an unfavorable prognosis of malignant pleural mesothelioma
M. Ma (2019)
10.3390/ijms19040988
NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma
T. Sato (2018)
10.3322/caac.21572
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
M. Carbone (2019)
10.3390/ijms19082191
Mesotheliomas in Genetically Engineered Mice Unravel Mechanism of Mesothelial Carcinogenesis
D. Jean (2018)
10.1097/CCO.0000000000000697
Malignant pleural mesothelioma: recent developments
K. Sinn (2020)
10.3390/cancers11101502
Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma
D. Xu (2019)
10.1016/j.critrevonc.2019.102815
Emerging therapies in malignant pleural mesothelioma.
M. Cinausero (2019)
10.1016/j.cllc.2019.08.003
Development of a Novel Prognostic Risk Classification System for Malignant Pleural Mesothelioma.
H. Doi (2019)
10.1016/j.ymthe.2019.05.020
MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis.
A. Singh (2019)
10.3857/roj.2019.00150
Preliminary results of entire pleural intensity-modulated radiotherapy in a neoadjuvant setting for resectable malignant mesothelioma
J. H. Hong (2019)
10.21037/tlcr.2020.02.03
SV40 and human mesothelioma.
M. Carbone (2020)
10.1158/2159-8290.CD-19-1220
Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer.
M. Carbone (2020)
10.1155/2019/1242964
Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma
Danijela Štrbac (2019)
10.1186/s13046-019-1352-3
Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma
C. Pulito (2019)
10.1007/978-3-319-96244-3_8
Care of the Mesothelioma Patient Undergoing Extended Pleurectomy and Decortication
M. Culligan (2019)
10.1016/j.thorsurg.2020.08.005
The Molecular Basis of Malignant Pleural Mesothelioma.
Benjamin Wadowski (2020)
10.1101/381533
Genome-wide silencing screen in mesothelioma cells reveals that loss of function of BAP1 induces chemoresistance to ribonucleotide reductase inhibition: implication for therapy
Agata Okonska (2018)
10.1177/0300891620941610
Ovarian metastasis from malignant pleural mesothelioma
Giuseppe Naldi (2020)
10.3390/ht7030020
Genomics and Epigenetics of Malignant Mesothelioma
Adam P Sage (2018)
10.1016/j.cllc.2019.10.013
Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy.
Juuso Paajanen (2019)
10.3390/cancers10040090
Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma
Y. Sekido (2018)
10.1016/j.lungcan.2018.11.034
Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018).
Licun Wu (2019)
10.1007/978-3-030-16884-1_6
Preclinical Models in Mesothelioma
I. F. Nerini (2019)
10.1002/ijc.32419
Wnt/IL‐1β/IL‐8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5
Vladan Milošević (2019)
10.1016/J.JTHO.2019.04.029
A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute–International Association for the Study of Lung Cancer–Mesothelioma Applied Research Foundation Taskforce
J. Friedberg (2019)
10.3390/ijerph15081741
Asbestos Exposure and the Mesothelioma Incidence in Poland
M. Krówczyńska (2018)
10.3390/cancers12071866
Targeting SRC Family Kinases in Mesothelioma: Time to Upgrade
P. Indovina (2020)
10.1016/j.jtho.2020.01.025
Comprehensive molecular and pathological evaluation of transitional mesothelioma assisted by deep learning approach: a multi institutional study of the International Mesothelioma Panel from MESOPATH Reference Center.
Francoise Galateau Salle (2020)
10.21037/jtd.2018.06.67
Personalized treatment of malignant mesothelioma-dream or reality?
A. Roden (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar